| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/28/2011 | US20110098356 Production and Purification of Esters of Polyunsaturated Fatty Acids |
| 04/28/2011 | US20110098349 Cathechins for the treatment of systemic aa amyloidosis |
| 04/28/2011 | US20110098335 Novel compounds |
| 04/28/2011 | US20110098333 Methods for treating or preventing brain infections |
| 04/28/2011 | US20110098330 Substituted-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors |
| 04/28/2011 | US20110098328 Heterocyclic derivatives as modulators of ion channels |
| 04/28/2011 | US20110098326 2-fluorothiazole derivatives useful as imaging agents; methods of synthesis, and methods of use |
| 04/28/2011 | US20110098319 Fatty acid derivatives for oral administration endowed with high palatability |
| 04/28/2011 | US20110098316 Chromane derivatives as trpv3 modulators |
| 04/28/2011 | US20110098313 Positive allosteric modulators (pam) |
| 04/28/2011 | US20110098311 Compositions for treatment of cystic fibrosis and other chronic diseases |
| 04/28/2011 | US20110098309 Methods of inhibiting the formation of amyloid-beta diffusable ligands using acylhydrazide compounds |
| 04/28/2011 | US20110098308 Azaindazole compounds and methods of use |
| 04/28/2011 | US20110098307 Crystalline of eszopiclone, its composition, preparation and uses thereof |
| 04/28/2011 | US20110098304 Small molecule inhibitors of PARP activity |
| 04/28/2011 | US20110098300 Compounds Comprising A Cyclobutoxy Group |
| 04/28/2011 | US20110098299 Spirolactam derivatives and uses of same |
| 04/28/2011 | US20110098295 Methods of treating anxiety, itching and psychiatric disorders |
| 04/28/2011 | US20110098292 New Compounds Useful for Treating CNS Disorders |
| 04/28/2011 | US20110098288 Sulfonamides as zap-70 inhibitors |
| 04/28/2011 | US20110098286 (3-aryl-piperazin-1-yl), (2-aryl-morpholin-4-yl) and (2-aryl-thiomorpholin-4-yl) derivatives of 6,7-dialkoxy-quinazoline, 6,7-dialkoxyphtalazine and 6,7-dialkoxyisoquinoline |
| 04/28/2011 | US20110098285 Bicyclic-substituted amines as histamine-3 receptor ligands |
| 04/28/2011 | US20110098284 Methods and compositions for treating pain |
| 04/28/2011 | US20110098282 New compounds |
| 04/28/2011 | US20110098281 Benzenesulfonyl Compounds and the Use Thereof |
| 04/28/2011 | US20110098278 Galantamine amino acid and peptide prodrugs and uses thereof |
| 04/28/2011 | US20110098276 Oxycarbamoyl compounds and the use thereof |
| 04/28/2011 | US20110098272 Novel Compounds As Casein Kinase Inhibitors |
| 04/28/2011 | US20110098269 Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands |
| 04/28/2011 | US20110098265 Methods for reducing cravings and impulses associated with addictive and compulsive behaviors |
| 04/28/2011 | US20110098262 Corroles for neuroprotection and neurorescue |
| 04/28/2011 | US20110098259 Pregnane steroids and their use in the treatment of cns disorders |
| 04/28/2011 | US20110098255 Combination of a parp inhibitor and an akt kinase activating compound |
| 04/28/2011 | US20110098254 Compositions comprising phospholipids |
| 04/28/2011 | US20110098253 Nitrosated Nonsteroidal Antiinflammatory Compounds, Compositions and Methods of Use |
| 04/28/2011 | US20110098237 Methods for inhibiting drug degradation |
| 04/28/2011 | US20110098236 Diamide inhibitors of cytochrome p450 |
| 04/28/2011 | US20110098228 Synthetic analogues of neural regeneration peptides |
| 04/28/2011 | US20110098227 Soluble notch-based substrates for gamma secretase and methods and compositions for using same |
| 04/28/2011 | US20110098226 Small molecular weight TNF receptor multimeric molecule |
| 04/28/2011 | US20110098225 NOVEL PEPTIDES DERIVED FROM NCAM (FGLs) |
| 04/28/2011 | US20110098223 Use of the pat nanopeptide in the treatment of autoimmune diseases |
| 04/28/2011 | US20110098213 Novel peptides for use in the treatment of obesity |
| 04/28/2011 | US20110098212 Cytokine |
| 04/28/2011 | US20110097428 Blended Compositions for Treatment of Alzheimer's Disease and Other Amyloidoses |
| 04/28/2011 | US20110097408 Chitosan-based matrices and uses thereof |
| 04/28/2011 | US20110097405 Estradiol-containing drug delivery system |
| 04/28/2011 | US20110097404 Tamper-resistant oral opioid agonist formulations |
| 04/28/2011 | US20110097395 Oral Pharmaceutical Compositions of Buprenorphine and Method of Use |
| 04/28/2011 | US20110097393 Skin Patches and Sustained-Release Formulations Comprising Lofexidine for Transdermal and Oral Delivery |
| 04/28/2011 | US20110097392 Antibody bound synthetic vesicle containing molecules for deliver to central and peripheral nervous system cells |
| 04/28/2011 | US20110097390 Ultra-Small RNAs as Toll-Like Receptor-3 Antagonists |
| 04/28/2011 | US20110097384 Transdermal drug delivery device including an occlusive backing |
| 04/28/2011 | US20110097351 Compounds for treating beta-amyloidoses |
| 04/28/2011 | US20110097347 Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of alzheimer's disease (ad) |
| 04/28/2011 | US20110097344 Compositions, Methods for Treatment, and Diagnoses of Autoimmunity-Related Disorders and Methods for Making Such Compositions |
| 04/28/2011 | US20110097331 Antibodies that bind both il-17a and il-17f and methods of using the same |
| 04/28/2011 | US20110097330 Novel Gene Disruptions, Compostitions and Methods Relating Thereto |
| 04/28/2011 | US20110097325 Modulation of T cell Differentiation for the treatment of T helper cell mediated diseases |
| 04/28/2011 | US20110097324 Compositions and methods for modulating nicotinic/nmda receptor function |
| 04/28/2011 | US20110097319 Antibody Capable of Binding Specifically to AB-Oligomer, and Use Thereof |
| 04/28/2011 | US20110097306 Oral formulations of cladribine |
| 04/28/2011 | DE102009043260A1 Pyridinyl-imidazolonderivate Pyridinyl-imidazolone derivatives |
| 04/28/2011 | DE102006031813B4 Verwendung basischer Acetophenone als Hemmstoffe von NO-Synthasen Using basic acetophenones as inhibitors of NO synthases |
| 04/28/2011 | CA2781522A1 Treatment using reprogrammed mature adult cells |
| 04/28/2011 | CA2779298A1 Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| 04/28/2011 | CA2779292A1 Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| 04/28/2011 | CA2778613A1 Methods and compositions for panic disorders |
| 04/28/2011 | CA2778484A1 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators |
| 04/28/2011 | CA2778483A1 Modulation of axon degeneration |
| 04/28/2011 | CA2778423A1 Alpha adrenergic receptor modulators |
| 04/28/2011 | CA2778401A1 Integrin alpha 8-beta 1-specific monoclonal antibody |
| 04/28/2011 | CA2778348A1 Novel compositions for preventing and/or treating degenerative disorders of the central nervous system |
| 04/28/2011 | CA2778256A1 Use of the combination of teriflunomide and glatiramer acetate for treating multiple sclerosis |
| 04/28/2011 | CA2778194A1 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives |
| 04/28/2011 | CA2778103A1 Donepezil-containing transdermal absorption formulation |
| 04/28/2011 | CA2778049A1 Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases |
| 04/28/2011 | CA2777881A1 Pyrazolopyrimidine derivatives |
| 04/28/2011 | CA2777551A1 Neuroprotection and myelin repair using nestorone |
| 04/28/2011 | CA2776480A1 Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators |
| 04/28/2011 | CA2775924A1 Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
| 04/27/2011 | EP2314697A1 Streptococcus pneumoniae proteins and nucleic acids |
| 04/27/2011 | EP2314689A2 Antisense compounds targeted to connexins and methods of use thereof |
| 04/27/2011 | EP2314673A1 Post-partum mammalian placenta, its use and placental stem cells therefrom |
| 04/27/2011 | EP2314627A2 Method for the treatment of multiple sclerosis |
| 04/27/2011 | EP2314609A1 Metastin derivative and use thereof |
| 04/27/2011 | EP2314601A1 Anti-inflammatory compounds and uses thereof |
| 04/27/2011 | EP2314585A1 Condensed benzamide compounds as inhibitors of vanilloid receptor subtype 1 (VR1) activity |
| 04/27/2011 | EP2314584A1 2-(heteroaryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| 04/27/2011 | EP2314571A2 Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents |
| 04/27/2011 | EP2314569A1 Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof |
| 04/27/2011 | EP2314321A1 Formulations comprising antisense nucleotides to connexins |
| 04/27/2011 | EP2314315A1 A blocking monoclonal antibody to the human alpha1 I-domain of VLA-1, and its use for the treatment of inflammatory disorders |
| 04/27/2011 | EP2314301A2 Sensitization of chemotherapeutic agent-resistant neoplastic cells with various viruses |
| 04/27/2011 | EP2314291A1 Use of the combination of teriflunomide and glatiramer acetate for treating multiple sclerosis |
| 04/27/2011 | EP2314290A1 Use of iron for treating attention deficit hyperactivity disorder in children |
| 04/27/2011 | EP2314289A1 Gaba receptor mediated modulation of neurogenesis |
| 04/27/2011 | EP2314288A1 Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
| 04/27/2011 | EP2314284A2 Cannabinoid liquid formulations for mucosal administration |
| 04/27/2011 | EP2313413A1 Pyrazolo [1, 5-a] pyrimidine derivatives |